Core Viewpoint - Tai Ling Pharmaceutical (01011.HK) has announced a suspension of trading of its shares on the Hong Kong Stock Exchange starting from 9:03 AM on February 10, 2026, at the company's request, pending the release of supplementary information regarding the announcement made on February 9, 2026, concerning the issuance of convertible bonds under general authorization [1] Group 1 - The trading suspension is effective immediately as of February 10, 2026 [1] - The suspension is related to the issuance of convertible bonds, indicating potential capital-raising activities by the company [1] - The announcement of supplementary information is expected to provide further clarity on the terms and implications of the convertible bonds [1]
泰凌医药(01011.HK)今早短暂停牌 待刊发有关发行可转换债券补充资料